Valeo Pharma Inc. announced that it has signed a licensing agreement with PharmaMar for the exclusive rights to commercialize Yondelis® (trabectedin), a novel marine-derived antitumor agent, to ensure uninterrupted supply of this important product in Canada. Under the terms of the agreement, Valeo shall pay a one-time licence payment to PharmaMar. PharmaMar will retain exclusive production rights and will sell the product to Valeo for commercial use.